M. Kalling

A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites

Nicoletta Colombo, Giorgia Mangili, Serafina Mammoliti et al. · Gynecologic Oncology · 2011 · 94 citations

Medicine, Gynecology, Oncology +16

Treatment of primary advanced and recurrent endometrial carcinoma with a combination of carboplatin and paclitaxellong-term follow-up

Bengt Sorbe, Henrik Andersson, Karin Boman et al. · International Journal of Gynecological Cancer · 2007 · 77 citations

Medicine, Oncology, Pharmacology +17

Chemotherapy vs tamoxifen in platinum-resistant ovarian cancer: a phase III, randomised, multicentre trial (Ovaresist)

Kristina Lindemann, Emma Gibbs, Elisabeth Åvall‐Lundqvist et al. · British Journal of Cancer · 2017 · 52 citations · Full text

Medicine, Oncology, Pharmacology +15

Aflibercept (VEGF Trap) for advanced epithelial ovarian cancer (EOC) patients (pts) with symptomatic malignant ascites: Preliminary results of a pilot study

N. Colombo, Giorgia Mangili, Serafina Mammoliti et al. · Journal of Clinical Oncology · 2008 · 26 citations

Medicine, Oncology, Pharmacology +17

Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene.

G. Horváth, U Stendahl, M. Kalling et al. · PubMed · 1990 · 10 citations

Pharmacy, Oncology, Pharmacology +16